Cybin Company Description

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.

It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.

The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds.

It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder.

The company is headquartered in Toronto, Canada.

Cybin Inc.

Country	Canada
Industry	Biotechnology
Sector	Healthcare
Employees	50
CEO	Douglas Drysdale

Contact Details

Address: 100 King Street West Toronto, Ontario M5X 1C9 Canada
Website	cybin.com

Stock Details

Ticker Symbol	CYBN
Exchange	Cboe Canada
Fiscal Year	April - March
Reporting Currency	CAD
ISIN Number	CA23256X1006
SIC Code	2834

Key Executives

Name	Position
Douglas L. Drysdale	Chief Executive Officer
Eric So L.L.B.	Co-Founder, President and Executive Chairman
Paul Glavine	Co-Founder, Chief Growth Officer and Director
Greg Cavers	Chief Financial Officer
Gabriel Fahel	Chief Legal Officer and Corporate Secretary
George Tziras	Chief Business Officer and Director
John Kanakis	Co-Founder
Aaron Bartlone	Chief Operating Officer
Dr. Alex L. Nivorozhkin Ph.D.	Chief Scientific Officer
Lori Challenger	Chief Compliance, Ethics and Administrative Officer